Zhejiang Starry Pharmaceutical Co.,Ltd. Stock Price

Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iodine-methyl, iodophorol, ioflufenicol, iopromide gadoxime meglumine, gadolinate dimeglumine, gadolinium, and iohexol injections; contrast agent APIs and intermediates consisting of iohexol, iopamidol, iodixanol, iodimeperidine, iopromide, iodophorol, iodophorol hydrolysate, iohexol hydrolysate, gadobacterium meglumine iodide, and triiodoisophthaloyl chloride esters; levofloxacin hydrochloride, levofloxacin, levofluorocycloester, and levofluorocarboxylic acid; and CMO and CDMO series, including loxoprofen sodium, loxoprofen acid, trimethyliodosilane, 2-iodo-5-methylbenzoic acid, methyl o-iodobenzoate, and iodobenzene. It also engages in technology promotion and application; investment; physical education; and wholesale activities. Zhejiang Starry Pharmaceutical Co.,Ltd. was incorporated in 1997 and is headquartered in Taizhou, China.